Active Ingredient History
Idelalisib is a first-in-class selective inhibitor of adenosine-5'-triphosphate (ATP) binding to PI3Kdelta kinase, resulting in inhibition of the P13K signalling pathway in malignant B cells. The compound is approved for the treatment of several types of blood cancer. Idelalisib is intended to be used in combination with rituximab as second or subsequent line therapy for the treatment of chronic lymphocytic leukaemia. The drug may cause fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Amyloidosis (Phase 2)
Anemia (Phase 1)
Breast Neoplasms (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Hodgkin Disease (Phase 2)
Immunoglobulin Light-chain Amyloidosis (Phase 2)
Leukemia, B-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 1)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Leukemia, Prolymphocytic (Phase 2)
Lymphoma (Phase 4)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 1)
Multiple Myeloma (Phase 1)
Myelodysplastic Syndromes (Phase 1)
Myeloproliferative Disorders (Phase 1)
Neoplasm Metastasis (Phase 1/Phase 2)
Neoplasms ()
Pancreatic Neoplasms (Phase 1)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Primary Myelofibrosis (Phase 1)
Recurrence (Phase 1/Phase 2)
Rhinitis, Allergic (Phase 1)
Squamous Intraepithelial Lesions (Phase 1)
Waldenstrom Macroglobulinemia (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue